A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local ...

The drug's development was funded by Novo Nordisk, the maker of popular semaglutide drugs like Ozempic and Wegovy. While ...

Goldman Sachs analyst James Quigley maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK875.00.

These companies have track records of success, increasing dividends, and fantastic growth prospects, making them all ideal ...

The global insulin delivery pen market is poised for remarkable growth, with its valuation projected to increase from USD ...

More obesity drugs are being launched this year following Novo Nordisk and Eli Lilly's previous successes with GLP-1 drugs.

Novo Nordisk A/S (NYSE:NVO – Get Free Report) was upgraded by equities researchers at UBS Group from a “sell” rating to a ...

Bagsværd, Denmark Friday, January 10, 2025, 11:00 Hrs [IST] ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

A bill to lower the price of insulin drugs and supplies for more North Dakotans attracted passionate discussion at a Thursday ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.